MiR-451 Suppresses Cell Proliferation and Metastasis in A549 Lung Cancer Cells

Molecular Biotechnology

Volumn 57, Issue 1, 2015, Pages 1-11

  Yin, Pin ^a   Peng, Rui ^a   Peng, Huimin ^a   Yao, Li ^a   Sun, Yan ^a   Wen, Li ^a   Wu, Tianhui ^a   Zhou, Ji ^a   Zhang, Zheng ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

Inflammation; Invasion; Lung cancer; MicroRNA; Migration

Indexed keywords

BIOLOGICAL ORGANS; CELL CULTURE; CELL PROLIFERATION; CELLS; PATHOLOGY; PLANTS (BOTANY); RNA; TISSUE REGENERATION;

INFLAMMATION; INVASION; LUNG CANCER; MICRORNAS; MIGRATION;

DISEASES;

CHEMOKINE RECEPTOR CXCR4; GELATINASE A; GELATINASE B; INDUCIBLE NITRIC OXIDE SYNTHASE; MICRORNA; MICRORNA 451; PROTEIN; PSMB8 PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN; 3' UNTRANSLATED REGION; LMP7 PROTEIN; MIRN451 MICRORNA, HUMAN; NOS2 PROTEIN, HUMAN; PROTEASOME;

3' UNTRANSLATED REGION; ARTICLE; BIOASSAY; BIOINFORMATICS; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DUAL LUCIFERASE REPORTER ASSAY; FLUORESCENCE MICROSCOPY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; LUCIFERASE ASSAY; LUNG CANCER CELL LINE; METASTASIS; MOLECULAR CLONING; MTT ASSAY; REAL TIME POLYMERASE CHAIN REACTION; RECOMBINANT PLASMID; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSWELL INVASION ASSAY; WESTERN BLOTTING; WOUND HEALING; WOUND HEALING ASSAY; APOPTOSIS; CELL CYCLE; CELL MOTION; GENE EXPRESSION REGULATION; GENETICS; LUNG TUMOR; METABOLISM; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; PATHOLOGY; PLASMID; TUMOR CELL LINE; TUMOR INVASION;

3' UNTRANSLATED REGIONS; APOPTOSIS; BASE SEQUENCE; CELL CYCLE; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MICRORNAS; MOLECULAR SEQUENCE DATA; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NITRIC OXIDE SYNTHASE TYPE II; PLASMIDS; PROTEASOME ENDOPEPTIDASE COMPLEX;

EID: 84937762560     PISSN: 10736085     EISSN: 15590305     Source Type: Journal    
DOI: 10.1007/s12033-014-9796-3     Document Type: Article

References (42)

1. Öberg, M., Jaakkola, M. S., Woodward, A., Peruga, A., & Prüss-Ustün, A. (2011). Worldwide burden of disease from exposure to second-hand smoke: a retrospective analysis of data from 192 countries. The Lancet,377(9760), 139–146.
2. Thill, P. G., Goswami, P., Berchem, G., & Domon, B. (2011). Lung cancer statistics in Luxembourg from 1981 to 2008. Bulletin de la Societe des Sciences Medicales du Grand-Duche de Luxembourg,2, 43–55.
3. Sterlacci, W., Fiegl, M., & Tzankov, A. (2012). Prognostic and predictive value of cell cycle deregulation in non-small-cell lung cancer. Pathobiology,79(4), 175–194.
4. Hussain, S. P., & Harris, C. C. (2007). Inflammation and cancer: an ancient link with novel potentials. International Journal of Cancer,121(11), 2373–2380.
5. Hattar, K., Savai, R., Subtil, F. S., Wilhelm, J., Schmall, A., Lang, D. S., et al. (2013). Endotoxin induces proliferation of NSCLC in vitro and in vivo: role of COX-2 and EGFR activation. Cancer Immunology, Immunotherapy,62(2), 309–320.
6. Cho, W. C., Kwan, C. K., Yau, S., So, P. P., Poon, P. C., & Au, J. S. (2011). The role of inflammation in the pathogenesis of lung cancer. Expert opinion on therapeutic targets,15(9), 1127–1137.
7. Houghton, A. M., Mouded, M., & Shapiro, S. D. (2008). Common origins of lung cancer and COPD. Nature Medicine,14(10), 1023–1024.
8. Lewis, B. P., Burge, C. B., & Bartel, D. P. (2005). Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell,120(1), 15–20.
9. Lu, J., Getz, G., Miska, E. A., Alvarez-Saavedra, E., Lamb, J., Peck, D., et al. (2005). MicroRNA expression profiles classify human cancers. Nature,435(7043), 834–838.
10. Contreras, J., & Rao, D. (2011). MicroRNAs in inflammation and immune responses. Leukemia,26(3), 404–413.
11. Garzon, R., Calin, G. A., & Croce, C. M. (2009). MicroRNAs in cancer. Annual Review of Medicine,60, 167–179.
12. Bergamaschi, A., & Katzenellenbogen, B. S. (2012). Tamoxifen downregulation of miR-451 increases 14-3-3ζ and promotes breast cancer cell survival and endocrine resistance. Oncogene,31(1), 39–47.
13. Bandres, E., Bitarte, N., Arias, F., Agorreta, J., Fortes, P., Agirre, X., et al. (2009). microRNA-451 regulates macrophage migration inhibitory factor production and proliferation of gastrointestinal cancer cells. Clinical Cancer Research,15(7), 2281–2290.
14. Lv G., Hu Z., Tie Y., Du J., Fu H., Gao X., et al. (2014). MicroRNA-451 regulates activating transcription factor 2 expression and inhibits liver cancer cell migration. Oncology Report. doi:10.3892/or.2014.3296.
15. Zhang, Z., Luo, X., Ding, S., Chen, J., Chen, T., Chen, X., et al. (2012). MicroRNA-451 regulates p38 MAPK signaling by targeting of Ywhaz and suppresses the mesangial hypertrophy in early diabetic nephropathy. FEBS Letters,586(1), 20–26.
16. Wang, R., Wang, Z., Yang, J., Pan, X., De, W., & Chen, L. (2011). MicroRNA-451 functions as a tumor suppressor in human non-small cell lung cancer by targeting ras-related protein 14 (RAB14). Oncogene,30(23), 2644–2658.
17. Solomides, C. C., Evans, B. J., Navenot, J. M., Vadigepalli, R., Peiper, S. C., & Wang, Z. X. (2012). MicroRNA profiling in lung cancer reveals new molecular markers for diagnosis. Acta Cytologica,56(6), 645–654.
18. Markou, A., Sourvinou, I., Vorkas, P., Yousef, G., & Lianidou, E. (2013). Clinical evaluation of microRNA expression profiling in non small cell lung cancer. Lung Cancer,81(3), 388–396.
19. Bian, H. B., Pan, X., Yang, J. S., Wang, Z. X., & De, W. (2011). Upregulation of microRNA-451 increases cisplatin sensitivity of non-small cell lung cancer cell line (A549). Journal of Experimental & Clinical Cancer Research,30(1), 20–31.
20. Megraw, M., Sethupathy, P., Corda, B., & Hatzigeorgiou, A. G. (2007). miRGen: a database for the study of animal microRNA genomic organization and function. Nucleic Acids Research,35(suppl 1), D149–D155.
21. Doench, J. G., Petersen, C. P., & Sharp, P. A. (2003). siRNAs can function as miRNAs. Genes & Development,17(4), 438–442.
22. Hua, Z., Lv, Q., Ye, W., Wong, C. K. A., Cai, G., Gu, D., et al. (2006). MiRNA-directed regulation of VEGF and other angiogenic factors under hypoxia. PLoS ONE,1(1), e116.
23. −ΔΔCt method. Methods,25(4), 402–408.
24. Elgamal, O. A., Park, J. K., Gusev, Y., Azevedo-Pouly, A. C. P., Jiang, J., Roopra, A., et al. (2013). Tumor suppressive function of mir-205 in breast cancer is linked to HMGB3 regulation. PLoS ONE,8(10), e76402.
25. Humplikova, L., Kollinerova, S., Papajik, T., Pikalova, Z., Holzerova, M., Prochazka, V., et al. (2013). Expression of miR-15a and miR-16-1 in patients with chronic lymphocytic leukemia. Biomedical Papers,157(4), 284–293.
26. Peng, W., Chen, Z., Wang, L., Wang, Z., & Li, J. (2013). MicroRNA-199a-3p is downregulated in gastric carcinomas and modulates cell proliferation. Genetics and molecular research: GMR,12(3), 3038.
27. Godlewski, J., Nowicki, M. O., Bronisz, A., Nuovo, G., Palatini, J., De Lay, M., et al. (2010). MicroRNA-451 regulates LKB1/AMPK signaling and allows adaptation to metabolic stress in glioma cells. Molecular Cell,37(5), 620–632.
28. Caudill, C. M., Jayarapu, K., Elenich, L., Monaco, J. J., Colbert, R. A., & Griffin, T. A. (2006). T cells lacking immunoproteasome subunits MECL-1 and LMP7 hyperproliferate in response to polyclonal mitogens. The Journal of Immunology,176(7), 4075–4082.
29. Moebius, J., van den Broek, M., Groettrup, M., & Basler, M. (2010). Immunoproteasomes are essential for survival and expansion of T cells in virus-infected mice. European Journal of Immunology,40(12), 3439–3449.
30. Singh, A. V., Bandi, M., Aujay, M. A., Kirk, C. J., Hark, D. E., Raje, N., et al. (2011). PR-924, a selective inhibitor of the immunoproteasome subunit LMP-7, blocks multiple myeloma cell growth both in vitro and in vivo. British Journal of Haematology,152(2), 155–163.
31. Song, L., Ma, N., Han, L., Yan, H., Yan, B., Yuan, Z., et al. (2013). Association between LMP2/LMP7 genetic variability and the metastasis risk of ovarian cancer in Chinese women in Beijing. Human Immunology,75(3), 239–244.
32. Fellerhoff, B., Gu, S., Laumbacher, B., Nerlich, A. G., Weiss, E. H., Glas, J., et al. (2011). The LMP7-K allele of the immunoproteasome exhibits reduced transcript stability and predicts high risk of colon cancer. Cancer Research,71(23), 7145–7154.
33. Zheng, F., Hasim, A., Anwer, J., Niyaz, M., & Sheyhidin, I. (2013). LMP gene promoter hypermethylation is a mechanism for its down regulation in Kazak’s esophageal squamous cell carcinomas. Molecular Biology Reports,40(3), 2069–2075.
34. Shen, Y. Q., Zhang, J. Q., Xia, M., Miao, F. Q., Shan, X. N., & Xie, W. (2007). Low-molecular-weight protein (LMP) 2/LMP7 abnormality underlies the downregulation of human leukocyte antigen class I antigen in a hepatocellular carcinoma cell line. Journal of Gastroenterology and Hepatology,22(7), 1155–1161.
35. Visekruna, A., Joeris, T., Schmidt, N., Lawrenz, M., Ritz, J. P., Buhr, H. J., et al. (2009). Comparative expression analysis and characterization of 20S proteasomes in human intestinal tissues: the proteasome pattern as diagnostic tool for IBD patients. Inflammatory Bowel Diseases,15(4), 526–533.
36. Visekruna, A., Joeris, T., Seidel, D., Kroesen, A., Loddenkemper, C., Zeitz, M., et al. (2006). Proteasome-mediated degradation of IkappaBalpha and processing of p105 in Crohn disease and ulcerative colitis. The Journal of Clinical Investigation,116(12), 3195–3203.
37. Schmidt, N., Gonzalez, E., Visekruna, A. A., Loddenkemper, C., Mollenkopf, H., Kaufmann, S. H., et al. (2010). Targeting the proteasome: partial inhibition of the proteasome by bortezomib or deletion of the immunosubunit LMP7 attenuates experimental colitis. Gut,59(7), 896–906.
38. Muchamuel, T., Basler, M., Aujay, M. A., Suzuki, E., Kalim, K. W., Lauer, C., et al. (2009). A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis. Nature Medicine,15(7), 781–787.
39. Kotamraju, S., Matalon, S., Matsunaga, T., Shang, T., Hickman-Davis, J. M., & Kalyanaraman, B. (2006). Upregulation of immunoproteasomes by nitric oxide: potential antioxidative mechanism in endothelial cells. Free Radical Biology and Medicine,40(6), 1034–1044.
40. Qureshi, A. A., Tan, X., Reis, J. C., Badr, M. Z., Papasian, C. J., Morrison, D. C., et al. (2011). Suppression of nitric oxide induction and pro-inflammatory cytokines by novel proteasome inhibitors in various experimental models. Lipids in health and disease,10(1), 177.
41. Lee, S. H., Jaganath, I. B., Manikam, R., & Sekaran, S. D. (2013). Inhibition of Raf-MEK-ERK and Hypoxia pathways by Phyllanthus prevents metastasis in human lung (A549) cancer cell line. BMC complementary and alternative medicine,13(1), 271.
42. Marrogi, A. J., Travis, W. D., Welsh, J. A., Khan, M. A., Rahim, H., Tazelaar, H., et al. (2000). Nitric oxide synthase, cyclooxygenase 2, and vascular endothelial growth factor in the angiogenesis of non-small cell lung carcinoma. Clinical Cancer Research,6(12), 4739–4744.